Serine protease inhibitors to treat inflammation: a patent review (2011-2016) [0.03%]
用于治疗炎症的丝氨酸蛋白酶抑制剂专利综述(2011-2016)
Feryel Soualmia,Chahrazade El Amri
Feryel Soualmia
Introduction: Inflammation is a physiological part of the complex biological response of tissues to counteract various harmful signals. This process involves diverse actors such as immune cells, blood vessels, and nerves ...
Bauhinia forficata in the treatment of diabetes mellitus: a patent review [0.03%]
宫股豆在糖尿病治疗中的应用：专利点评
Bárbara Verônica Cardoso de Souza,Regilda Saraiva Dos Reis Moreira Araújo,Oskar Almeida Silva et al.
Bárbara Verônica Cardoso de Souza et al.
Introduction: Diabetes Mellitus has been considered an epidemic by the World Health Organization, with a high risk of morbidity and mortality. The treatment of this pathology consists in glycemic control, which can be don...
Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings [0.03%]
GSK黄嘌呤氧化酶抑制剂及其晶型专利族评价：WO2017098421
Ya-Ping Gong,Ren-Zhong Wan,Zhao-Peng Liu
Ya-Ping Gong
There are considerable interests in the development of novel small-molecule CD73 inhibitors for the treatment of cancers, autoimmune diseases, precancerous syndromes, and other diseases associated with CD73 activity. Areas covered: The appl...
Diabetes area patent participation analysis - part II: years 2011-2016 [0.03%]
糖尿病领域专利参与分析——第二部分：2011—2016年
Markus Boehm,Matthew Crawford,Jamie E Moscovitz et al.
Markus Boehm et al.
Introduction: Diabetes is a metabolic disease characterized by elevated levels of plasma glucose. When untreated, diabetes increases the risk of developing co-morbidities such as cardiovascular disease. Several drugs, oft...
Xun Li
Xun Li
Introduction: Gelatinase represents a promising biotarget in new drug development as it is closely related to various pathological events, including but not limited to neoplasm, aging, respiratory and neurological disorde...
Statement of Retraction [0.03%]
撤稿声明
Retraction of Publication
Expert opinion on therapeutic patents. 2017 Dec;27(12):1363. DOI:10.1080/13543776.2017.1294367 2017
A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017) [0.03%]
2013-2017年单酰基甘油脂肪酶(MAGL)抑制剂专利回顾分析
Carlotta Granchi,Isabella Caligiuri,Filippo Minutolo et al.
Carlotta Granchi et al.
Monoacylglycerol lipase is a serine hydrolase that plays a major role in the degradation of the endocannabinoid 2-arachidonoylglycerol. Because of this key role, selective inactivation of MAGL represents an interesting approach to obtain de...
Haider Behbehani,Kamal M Dawood,Thoraya A Farghaly
Haider Behbehani
Introduction: Several natural products containing benzosuberone moiety are clinically reported as anti-tumor agents. Furthermore, several synthetic benzosuberones cited in this review exhibited wide range of theraputic ac...
Pyruvate kinase activators as a therapy target: a patent review 2011-2017 [0.03%]
丙酮酸激酶激活剂作为治疗靶点的专利回顾(2011-2017)
Sevki Adem,Veysel Comakli,Naim Uzun
Sevki Adem
Introduction: It is well known that cancer cells have an altered metabolism both to meet the energy needs and to provide initial molecules for the synthesis of macromolecules. To cope with the new metabolic state, differe...
Bill C-30: who wins and who loses in Canada's pharmaceutical patent battles? [0.03%]
加拿大药品专利之争：赢家与输家都是谁？
Aidan Hollis
Aidan Hollis